Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses from here.
See our full analysis for Zepp Health.With the headline numbers on the table, the next step is to line them up against the most widely held narratives around Zepp Health to see which views the results support and which they put under pressure.
See what the community is saying about Zepp Health
US$258.9m in sales but TTM loss still US$40.1m
- Over the last twelve months to Q4 2025, Zepp Health generated US$258.9 million in revenue and reported a net loss of US$40.1 million, compared with a Q4 2025 quarterly net loss of US$11.0 million on US$85.2 million of revenue.
- Analysts' consensus view highlights product upgrades and premium expansion as key earnings drivers. However, the trailing twelve month loss of US$40.1 million and the Q1 2025 loss of US$19.7 million on US$38.5 million of revenue show how far reported results still are from the long term margin ambitions.
- Consensus points to product innovation and premium segment expansion as supports for future earnings. At the same time, the trailing twelve month basic EPS loss of US$2.52 underlines that these efforts have not translated into profitability yet.
- Comments about rising costs and regulatory pressures match the pattern of multi period losses, with net income remaining negative in every quarter from Q3 2024 through Q4 2025 while revenue moved between US$38.5 million and US$85.2 million.
TTM losses and a 53.8% annualized earnings decline
- Over the past five years, net losses have worsened at an annualized rate of 53.8%, and the latest trailing twelve month net loss of US$40.1 million and basic EPS loss of US$2.52 confirm the business is still operating at a loss.
- Bears argue that persistent losses and no expected profitability within three years are a key risk. The sequence of quarterly losses from US$36.9 million in Q4 2024 to a range of US$10.0 million to US$20.0 million per quarter through 2025 aligns with that concern.
- Critics highlight that even as quarterly revenue ranged from US$38.5 million in Q1 2025 to US$85.2 million in Q4 2025, every quarter remained loss making. This fits the view that higher sales alone may not be enough to reach profitability quickly.
- The provided assessment that management is not projected to reach profitability within three years is consistent with the trailing twelve month loss pattern and the multi year 53.8% annualized deterioration in earnings.
P/S at 0.9x versus industry 2.4x
- Zepp Health trades on a P/S of 0.9x, compared with the US Electronic industry average of 2.4x and a peer average of 9x, so the current US$16.22 share price sits on a lower sales multiple than those reference points.
- Supporters of a more bullish stance often point to brand upgrades, premium devices and AI driven health features as reasons the business could eventually justify higher valuation multiples. The 0.9x P/S combined with US$258.9 million of trailing twelve month revenue is the main anchor for that view.
- Consensus narrative mentions premium segment expansion and AI powered analytics as drivers of higher margin potential, which some may weigh against the current discount to the 2.4x industry P/S level.
- At the same time, the company’s unprofitable status and highly volatile share price over the past three months explain why the market may be keeping the P/S closer to 0.9x rather than closer to peer levels.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Zepp Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If the mix of bullish and bearish arguments feels finely balanced, it helps to look at the numbers yourself and test each claim against the data. To weigh those concerns in detail before the market moves on, make time to review the 3 important warning signs.
Explore Alternatives
Zepp Health is still reporting multi period net losses, with trailing twelve month EPS in the red and no projected profitability within three years.
If you want ideas where profitability and balance sheets already look more resilient, check out the 74 resilient stocks with low risk scores to compare companies side by side today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com